Equities Analysts Offer Predictions for AKBA Q2 Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for Akebia Therapeutics in a research report issued on Wednesday, June 4th. HC Wainwright analyst M. Caufield expects that the biopharmaceutical company will earn ($0.01) per share for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics' Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.02) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.41 EPS and FY2029 earnings at $0.52 EPS.

A number of other equities analysts have also issued reports on AKBA. Leerink Partners assumed coverage on shares of Akebia Therapeutics in a research report on Monday, April 28th. They set an "outperform" rating and a $7.00 target price on the stock. Leerink Partnrs upgraded shares of Akebia Therapeutics to a "strong-buy" rating in a research report on Monday, April 28th. Wall Street Zen upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 3rd. Piper Sandler upped their target price on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Finally, Jefferies Financial Group initiated coverage on shares of Akebia Therapeutics in a report on Tuesday, April 1st. They issued a "buy" rating and a $6.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Akebia Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $6.75.

Akebia Therapeutics Price Performance

Shares of AKBA stock traded up $0.28 during trading hours on Friday, reaching $3.97. 8,174,539 shares of the company were exchanged, compared to its average volume of 3,077,858. Akebia Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.00. The stock's fifty day moving average is $2.44 and its two-hundred day moving average is $2.15. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -17.26 and a beta of 0.85.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.06. The company had revenue of $57.34 million for the quarter, compared to analyst estimates of $44.88 million.

Insider Activity at Akebia Therapeutics

In related news, CAO Richard C. Malabre sold 13,334 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $3.53, for a total value of $47,069.02. Following the transaction, the chief accounting officer now directly owns 266,914 shares in the company, valued at $942,206.42. This represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Akebia Therapeutics

Several large investors have recently bought and sold shares of the business. SRS Capital Advisors Inc. acquired a new stake in Akebia Therapeutics in the fourth quarter worth $26,000. Mariner LLC acquired a new stake in Akebia Therapeutics in the fourth quarter worth $28,000. PDS Planning Inc acquired a new stake in Akebia Therapeutics in the fourth quarter worth $28,000. Unified Investment Management raised its holdings in Akebia Therapeutics by 47.8% in the first quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 5,500 shares during the period. Finally, E Fund Management Co. Ltd. raised its holdings in Akebia Therapeutics by 51.9% in the first quarter. E Fund Management Co. Ltd. now owns 19,311 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 6,595 shares during the period. 33.92% of the stock is currently owned by institutional investors and hedge funds.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.